Clinical/Research Interests

A researcher as well as a surgical oncologist, Dr. Bold is an expert in pancreatic and hepatobiliary cancers, breast cancer and the application of minimally invasive surgical techniques to the patient with cancer. He oversees an active basic-science laboratory investigating mechanisms of resistance to traditional chemotherapy as well as testing new treatments for detecting and treating cancer. He has published extensively in the areas of apoptosis, metastasis, and the cellular biology of pancreatic and lung cancers. He also is the principal investigator for the American College of Surgeons Oncology Group (ACOSOG) at UC Davis and is an integral member of the Clinical Trials Group at the UC Davis Cancer Center.

Dr. Bold has implemented a variety of minimally invasive techniques used in the surgical treatment of patients with various tumors (both benign and malignant). This includes the sentinel lymph-node biopsy procedure for women with breast cancer and a variety of laparoscopic procedures for abdominal tumors, including laparoscopic adrenalectomy, splenectomy and pancreatectomy.

Specialty:

Center/Program Affiliation:

Address:

Phone:

Education:

Internships:

Residency:

Fellowships:

Board Certifications:

Professional Memberships:

Select Recent Publications:

Galante, J.M., M.M. Mortenson, T.L. Bowles, S. Virudachalam, R.J. Bold. ERKlBCL-2 pathway in the resistance of pancreatic cancer to anoikis. J Surg Res, 152:18-25. 2009.

Coates JM, Beal SH, Russo JE, Vanderveen KA, Chen SL, Bold RJ, Canter RJ. Negligible effect of selective preoperative biliary drainage on peri operative resuscitation, morbidity, and mortality in patients undergoing pancreaticoduodenectomy. Arch Surg, 144:841-7. 2009.

Kim, R.H., R.J. Bold, and H-J. Kung. ADI, autophagy and apoptosis: Metabolic stress as a therapeutic option for prostate cancer. Autophagy, 5:567-8. 2009.

Hauser SH, CK Abbey, R.J. Bold, MK Gagnon, J Marik, JF Marshall, CE Stanecki, JL Sutcliffe. Targeted in vivo imaging of integrin avB6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res, 69:5843-50. 2009.

Kim, R.H., J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, J.u. Jung, R Gandour-Edwards, F.Y.S. Chuang, R.J. Bold, and H-J. Kung. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspaseindependent apoptosis. Cancer Research, 69(2):700-708. 2009.

Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer. Jun 1;115(11):2420-9. 2009.

Bowles, T.L., R Kim, J. Galante, C.M. Parsons, S. Virudachalam, H-J. Kung, R.J. Bold. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. lnt J Cancer, 123:1950-1955. 2008.

Parsons, C.M., J.L. Sutcliffe, R.J. Bold. Preoperative evaluation of pancreatic adenocarcinoma. J Hepato-Biliary-Pancreatic Surg, 15:429-435. 2008.

Vanderveen, K., R Ramsamooj, R.J. Bold. A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancer. Ann Surg Oncol, 15(7):2006-2011. 2008.

Vanderveen, K., R.J. Bold. Effect of generational composition on the surgical workforce. Arch Surg, 143(3)224-226. 2008.